Education
About Us
Working with TipRanks
Follow Us
Saniona AB (DE:30S)
FRANKFURT:30S
30S Stock Chart & Stats
€1.93
>-€0.01(-0.49%)
At close: 4:00 PM EST
€1.93
>-€0.01(-0.49%)
Day’s Range― - ―
52-Week Range€0.48 - €2.58
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€329.51M
Enterprise Value€2.82B
Total Cash (Recent Filing)€672.75M
Total Debt (Recent Filing)€268.00K
Price to Earnings (P/E)5.7
Beta-1.11
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding138,030,140
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.69
Price to Sales (P/S)2.56
P/FCF Ratio3.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationSaniona’s operating and free cash flow turned strongly positive in 2024 and TTM, with FCF close to net income. Durable cash generation improves runway, funds discovery and clinical work internally, and reduces near-term dilution risk versus peers reliant on continual financings.
Revenue And Profitability InflectionThe company recorded a material operating and net income turnaround in 2024/TTM alongside meaningful revenue acceleration. If sustained, this supports reinvestment in the pipeline and strengthens credibility with partners, lowering execution risk on future deals and milestones.
Partnering/licensing Business ModelA licensing/partnering model reduces commercialization burden and caps internal capex needs. Upfronts, milestones and potential royalties create non-linear upside tied to partner development and approvals, enabling value capture from R&D without large-scale sales infrastructure.
Bears Say
Profitability Volatility HistoryThe sharp 2024/TTM profit swing follows several years of deep losses and negative margins. In biotech, one-off license gains or timing of milestones can create episodic profits, so earnings and margins may revert or be lumpy absent sustained commercial revenue streams.
Capital Structure InstabilityWhile leverage improved recently, the history of negative equity and prior high leverage indicates past financing stress. That legacy increases the probability of future financing needs or dilution if cash generation falters, constraining long-term financial resilience.
Small Scale And Partner RelianceA very small team and a model focused on out-licensing mean limited internal commercialization capability and operational scale. Business performance can hinge on a few partnership outcomes, concentrating execution risk and making revenue more binary and less diversified.
Saniona AB News
30S FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was €0.48 and its highest was €2.58 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is €329.51M.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Feb 26, 2026 which is in 8 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Nov 27, 2025. The company reported €0.226 earnings per share for the quarter, beating the consensus estimate of N/A by €0.226.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of €0.226 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in DE:30S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---